EyePoint CMO exercises options, sells 2,437 shares

EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported a set of option-related transactions.

Rhea-AI Filing Summary

EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported a set of option-related transactions. On February 17, 2026, he exercised stock options and acquired 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares in an open-market transaction at $15.00 per share. Following these moves, he reported holding 85,313 stock options and no directly held common shares from this transaction. A disclosed option award vests 25% on January 3, 2026, with the remainder vesting monthly over the next three years.

Insider Trade Summary

Exercise and Sale: 2,437 shares ($16K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ribeiro Ramiro

Role Chief Medical Officer

Sold 2,437 shs ($37K)

Approx. gross sale proceeds $37K

Approx. exercise cost $20K

Approx. pre-tax spread $16K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,437	$0.00	$0.00
Exercise	Common Stock	2,437	$8.26	$20K
Sale	Common Stock	2,437	$15.00	$37K

Holdings After Transaction: Stock Option (Right to Buy) — 85,313 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (1)

1. F1. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

FAQ

What insider transactions did EyePoint (EYPT) report for Ramiro Ribeiro?

EyePoint’s Chief Medical Officer Ramiro Ribeiro exercised options for 2,437 shares and sold 2,437 common shares on February 17, 2026. These transactions reflect an option exercise followed by an open-market sale of the resulting shares at $15.00 per share.

How many EyePoint (EYPT) shares did the CMO sell in this Form 4?

The Chief Medical Officer sold 2,437 shares of EyePoint common stock. The sale occurred on February 17, 2026 at a price of $15.00 per share, immediately after exercising options that had produced the same number of shares.

At what price did the EyePoint (EYPT) CMO exercise and sell shares?

The CMO acquired 2,437 shares through an option exercise at $8.26 per share and then sold 2,437 shares at $15.00 per share. Both transactions took place on February 17, 2026 according to the reported Form 4 data.

How many EyePoint (EYPT) stock options does the CMO hold after these trades?

After the reported transactions, the Chief Medical Officer held 85,313 stock options. This figure reflects the remaining derivative securities reported following the option exercise of 2,437 options into common shares on February 17, 2026.

Did EyePoint (EYPT) indicate any vesting schedule for the CMO’s options?

Yes. One option to purchase shares vests 25% on January 3, 2026, with the remaining 75% vesting ratably on a monthly basis over the following three years, according to the disclosed footnote in the Form 4.

Does this EyePoint (EYPT) Form 4 show net buying or selling by the CMO?

The Form 4 shows a net sale of 2,437 common shares. While the CMO acquired shares through an option exercise, he sold the same number of shares at $15.00 each, resulting in zero net common shares from this set of transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ribeiro Ramiro

(Last) (First) (Middle)

C/O EYEPOINT, INC

480 PLEASANT STREET, SUITE C400

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EyePoint, Inc. [ EYPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M		2,437	A	$8.26	2,437	D
Common Stock	02/17/2026		S		2,437	D	$15	0.00	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.26	02/17/2026		M			2,437	(1)	01/03/2035	Common Stock	2,437	$0.00	85,313	D

Explanation of Responses:

1. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.